GP40321 + Apidra® SoloStar® + RinGlar®
Phase 3Completed 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Type 1 Diabetes Mellitis
Conditions
Type 1 Diabetes Mellitis
Trial Timeline
Apr 14, 2023 → Nov 28, 2023
NCT ID
NCT07070752About GP40321 + Apidra® SoloStar® + RinGlar®
GP40321 + Apidra® SoloStar® + RinGlar® is a phase 3 stage product being developed by GEROPHARM for Type 1 Diabetes Mellitis. The current trial status is completed. This product is registered under clinical trial identifier NCT07070752. Target conditions include Type 1 Diabetes Mellitis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07070752 | Phase 3 | Completed |
Competing Products
20 competing products in Type 1 Diabetes Mellitis